Vivo Capital, LLC Q3 2016 Filing
Filed November 14, 2016
Portfolio Value
$320.9B
Holdings
22
Report Date
Q3 2016
Filing Type
13F-HR
All Holdings (22 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | ACRSAclaris therapeutics | 4,191,397 | $107.3B | 33.45% | |
| 2 | ASNDAscendis Pharma | 1,766,832 | $35.5B | 11.07% | |
| 3 | CLDNEUREiger BioPharmaceuticals | 1,787,091 | $23.9B | 7.46% | |
| 4 | CDXSCodexis, Inc. | 5,294,825 | $23.5B | 7.33% | |
| 5 | —Nabriva Therapeutics AG | 3,151,700 | $22.2B | 6.92% | |
| 6 | —Advanced Accelerator Applications S.A. | 455,798 | $17.4B | 5.41% | |
| 7 | —Agile Therapeutics, Inc. | 2,019,955 | $14.1B | 4.39% | |
| 8 | RGNXRegenxbio Inc. | 990,449 | $13.9B | 4.32% | |
| 9 | —Trevena, Inc. | 1,728,000 | $11.7B | 3.63% | |
| 10 | —Aimmune Therapeutics, Inc. | 763,009 | $11.4B | 3.57% | |
| 11 | —CoLucid Pharmaceuticals, Inc. | 225,000 | $8.6B | 2.68% | |
| 12 | —Foamix Pharmaceuticals Ltd. | 855,000 | $7.9B | 2.47% | |
| 13 | —Capnia, Inc. | 7,456,984 | $6.7B | 2.09% | |
| 14 | —Akari Therapeutics Plc | 527,842 | $4.5B | 1.40% | |
| 15 | —ProNAi Therapeutics, Inc. | 2,438,270 | $4.4B | 1.38% | |
| 16 | DVAXDynavax Technologies Corporation | 359,828 | $3.8B | 1.18% | |
| 17 | —Carbylan Therapeutics | 4,204,562 | $1.9B | 0.60% | |
| 18 | RVNCEURReVance Therapeutics, Inc. | 77,373 | $1.3B | 0.39% | |
| 19 | —Ocera Therapeutics, Inc. | 153,331 | $405.0M | 0.13% | |
| 20 | —Capnia, Inc. | 943,858 | $198.0M | 0.06% | |
| 21 | —Palatin Technologies, Inc. | 234,909 | $148.0M | 0.05% | |
| 22 | —Zosano Pharma Corp | 98,515 | $78.0M | 0.02% |